Recommendations to choose the primary endpoint in cardiovascular clinical trials by Gómez Melis, Guadalupe et al.
  
 
 
 
 
 
 
 
 
 
 
Recommendations to choose the primary  
endpoint in cardiovascular clinical trials 
 
Guadalupe Gómez Melis1, Moisés Gómez-Mateu1, Urania Dafni2 
 
1Dept. of Statistics and Operations Research 
Universitat Politècnica de Catalunya 
Jordi Girona 1–3, 08034 Barcelona, Catalonia (Spain) 
2University of Athens, Hellas, Athens (Greece) 
Report DR 2013/08 
December 2013 
Report 
 
 
 
 
 
 
 
 
 Recommendations to choose the primary endpoint in 
cardiovascular clinical trials 
Guadalupe Gómez, PhD*; Moisés Gómez-Mateu, MSc*; Urania Dafni, ScD** 
 
	
	
	
	
	
	
	
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* From the Department of Statistics and Operations Research, Universitat Politècnica de Catalunya. Barcelona, Spain; and  
** University of Athens, Hellas, Athens, Greece. 
Correspondence to Guadalupe Gómez, PhD, Jordi Girona 1-3, 08304, Barcelona. E-mail lupe.gomez@upc.edu. 
 
 
3 
 
Abstract 
 
Background – A composite endpoint is often used as the primary endpoint to 
assess the efficacy of a new treatment in randomized clinical trials (RCT). In 
cardiovascular trials, the often rare event of the relevant primary endpoint 
(individual or composite), such as cardiovascular death (CV death), 
Myocardial Infarction (MI), or both, is combined with a more common 
secondary endpoint, such as target lesion revascularization, with the aim to 
increase the statistical power of the study.  
Methods – Gómez and Lagakos developed statistical methodology to be used 
at the design stage of a RCT for deciding whether to expand a study 
relevant primary endpoint ε1 to ε*, the composite of ε1 and a secondary 
endpoint ε2. The method uses the asymptotic relative efficiency of the 
logrank test for comparing treatment groups based on ε1 versus the logrank 
test based on ε*. The method is used to assess, in the cardiovascular 
research area, the characteristics of the candidate individual endpoints that 
should govern the choice of using a composite endpoint as the primary 
endpoint in a clinical trial. 
Results and conclusions – A set of recommendations is provided based on 
the reported values of the frequencies of observing each candidate endpoint 
as well as on the magnitude of the effect of treatment as expressed by the 
hazard ratio, supported by cardiovascular RCTs published in 2008.  
Key words: Asymptotic Relative Efficiency; Composite outcome; Logrank test; 
Cardiovascular; Randomized Clinical Trial	
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Introduction 
The conclusions of a clinical trial rely heavily on its primary endpoint, and thus, at the 
design phase is of outmost importance that the most appropriate choice of primary 
endpoint is made. Composite endpoint (CE) is an event that is considered to have 
occurred if any one of several different events or outcomes (components) is 
observed1,2. CEs are nowadays used commonly as the primary endpoint to assess 
the efficacy of a new treatment. In cardiovascular trials, a CE is more often used than 
not, incorporating either terminal outcomes, death from any cause, cardiovascular 
death (CV death) or not, such as Myocardial Infarction (MI), stroke and 
hospitalization. One could argue that the aim of using a CE is to address all efficacy 
measures deemed relevant to the success of a new treatment without the limitations 
imposed by multiplicity and competing risks problems. Nevertheless, one of the main 
objectives is to increase the power to detect a significant benefit induced by the new 
treatment. This increase, in the case of time-to-event endpoints, is expected to be 
achieved by the inclusion of component endpoints that occur with higher frequency 
and/or earlier than the main events of interest3. However, adding less specific 
components might in fact lead to loss of power to detect the true treatment 
differences. In addition, improvement in the composite does not necessarily translate 
to an improvement in the relevant component (e.g., overall survival). The use of a CE 
is furthermore intricate due to the possibly big difference in the relative importance of 
the components as well as in the respective magnitude of the treatment effect.  
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Gómez & Lagakos4, provided a methodology to reach an informed decision 
regarding the primary endpoint at the design stage of a clinical trial. In the current 
manuscript, an illustration of this statistical methodology is presented and used to 
provide guidelines for the informed choice of primary endpoint in the context of 
cardiovascular clinical trials.  
	
Statistical Method 
Consider a two-arm RCT involving random assignment either to an active treatment 
or to a control treatment. We have a study relevant endpoint (RE), ε1, that could be 
used as the primary endpoint for efficacy and a secondary endpoint which could be 
viewed as an additional endpoint of interest (AE), ε2. For example, assume RE is the 
composite of cardiovascular death and MI, (ε1), while AE is target lesion 
revascularization (ε2). We consider the CE ε* of ε1 and ε2. The individuals are followed 
from randomization until the event of interest, or until the end of study, whichever 
occurs first.  
To make an informed decision on whether the RE ε1 or the CE ε* should be the 
primary endpoint, Gómez and Lagakos4 develop a strategy based on the behavior of 
the asymptotic relative efficiency of the logrank test for comparing treatment groups 
with respect to ε1 versus the logrank test with respect to ε*, denoted by ARE(ε* ,ε1). 
The computations for the ARE depend on a) whether or not the two endpoints of 
interest include a terminal event (death), b) the probabilities p1 and p2 of observing 
events ε1 and ε2, respectively, for the control group, c) the treatment effect with 
respect to ε1 and ε2 given by the hazard ratios HR1 and HR2, and d) the correlation 
between the times to event ε1 and ε2.  
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Gómez and Lagakos4 propose as a general rule to use the CE instead of the 
RE if ARE(ε* ,ε1)>1.1; and to retain the RE, if ARE(ε* ,ε1)≤1.1. 
	
Composite Endpoints in Cardiovascular Research 
Freemantle3 acknowledges the inadequate reporting of CEs used as primary 
outcome measures in randomized trials, concluding that, often, the reported results 
apply to the individual components of the CE rather than to the overall CE. In a 
meta-analysis exploring the use of CE in cardiovascular research, 114 interventional 
RCTs, almost half of the total cardiovascular trials examined, were identified to use a 
CE as the primary trial endpoint 5. In the conclusions, it is stated that the use of CE is 
often complicated by the magnitude of the effect of treatment across component 
endpoints as well as by the relative importance of the different components for the 
patients. Furthermore, it is discussed how higher event rates and larger treatment 
effects associated with less important components may lead to a misleading 
impression of the treatment effect.  
	
Material and Methods	
The extent of use of CEs in the recent literature was explored through a systematic 
Medline search covering the 2008 year publication of RCTs in 6 high impact medical 
journals (see Table 1). Medline search, was restricted to “randomized controlled trial” 
and “human” subjects publications including the terms coronary artery disease, 
valvular heart disease, arrhythmia, cardiomyopathy, congestive, heart failure, 
cardiovascular, or cardiovascular disease in the abstract, title or keywords. The 
systematic search resulted to 216 publications. From these, 87 mentioned in the 
abstract, title or keywords, a composite or combined endpoint, or the specific 
endpoints of MACE (Major Adverse Cardiac Events), or NACE (Net Adverse Clinical 
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Events). Papers that dealt with other diseases, looked at subgroup or nonrandomized 
comparisons or did not use time to event endpoints were excluded. A total of 61 
clinical trials, were considered for exploring the use of a CE. The breakdown by 
journal is presented in Table 1. See the complete reference list in the appendix. 
	
	
JOURNAL  
(Papers and RCT) Total papers %  CE RCT % 
NEJM 46 21% 17 28% 
THE LANCET 36 17%  13 21% 
European Heart Journal 54 25% 12 20% 
CIRCULATION 53 25% 10 16% 
JAMA 24 11% 9 15% 
Annals of Internal Medicine 3 1% 0 0% 
Total RCT 216 100%  61 100% 
 
Table 1: Summary of Medline search, for Cardiovascular terms, for 2008 publications of Randomized Clinical Trials (RCT). CE 
stands for Composite Endpoint. 
	
A CE was used as primary endpoint for 47 of the clinical trials and as 
secondary for the remainder of 14 clinical trials. The frequency of use of different 
CEs, as well as of each individual component, for the cases that CE is the primary, is 
presented in Table 2. MI and Stroke were encountered as components of the CE in 
over half of these clinical trials (66% and 55%, respectively), while death is 
encountered in all of them but one (98%). In addition, among the 14 trials with an 
individual primary endpoint, in 13 of them death is either the relevant (in 4) or used as 
an additional endpoint (in 9).  
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Endpoint combinations  DEATH MI STROKE HOSPITALIZATION TVR 
N with 
additional 
endpoints 
N Total (%) 
1 X X X     8 14 (30%) 
2 X X X X   5 8 (17%) 
4 X     X   1 6 (13%) 
3 X X       2 5 (11%) 
5 X         5 5 (11%) 
6 X X     X 2 4 (9%) 
7 X   X     2 2 (4%) 
8 X       X 1 1 (2%) 
9 X   X   X 1 1 (2%) 
10     X     1 1 (2%) 
98% 66% 55% 30% 13% 28 47 
 
Table 2: Frequencies for different combinations of endpoints for 47 RCTs with CE as primary endpoint. TVR stands for Target 
Vessel Revascularization. 
	
It is thus clear that in the cardiovascular context, the CEs under consideration 
overwhelmingly include a terminal event either as a relevant or as an additional 
endpoint. Two clinical trials are used as case studies in the next section: the first, with 
death as component of the primary CE, and the second with death as component of 
the secondary CE. 
 
Case Study 1: Treating patients after an acute coronary syndrome with 
succinobucol 
A RCT to assess the effects of the antioxidant succinobucol (AGI-1067) on 
cardiovascular outcomes in patients with recent acute coronary syndrome already 
managed with conventional treatments, uses as primary endpoint, denoted by ε*, the 
composite of ε1 (time to first occurrence of cardiovascular death, resuscitated cardiac 
arrest, MI, stroke), and ε2 (unstable angina or coronary revascularization) (see Figure 
1) 6. A total of 6144 patients having experienced an acute coronary syndrome up to 
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one year before recruitment, were randomized to receive succinobucol (n=3078) or 
placebo (n=3066), in addition to standard of care. The arguably more important 
components of the primary CE, denoted by ε1, are cardiovascular death, resuscitated 
cardiac arrest, MI, or stroke, comprising one of three secondary CEs. A beneficial 
effect of succinobucol on ε1 was found [207 events: succinobucol vs 252 
events:placebo; hazard ratio (HR) = 0.81, p = 0.029]. The less important but frequent 
outcomes, i.e., hospitalization for unstable angina and coronary revascularization, 
denoted by ε2, were included in the primary CE ε*. The expectation would be that by 
the inclusion of these outcomes, the resulting increase in the number of CE events 
observed would lead to an increase in study power. On the contrary, these endpoints 
did not differ significantly between the two treatment groups, and their contribution of 
a high relative number of events in the primary CE (64%), led to the disappearance of 
the statistically significant benefit of the active treatment on the important outcomes 
ε1. Thus, the primary CE, ε*, was not found to be significantly different between treat-
ment groups (530 events:succinobucol vs 529 events:placebo).  
	
	
 
Figure 1: Composite Endpoint ε* as the union of the Relevant endpoint (ε1) and the Additional Endpoint (ε2) in Tardif´s RCT. 
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Using the notation we have introduced in the previous section, we have that 
the probability of observing the RE ε1, is p1 = 8.2% with observed HR1 =0.81, while 
the probability of observing the AE ε2, is p2 = 10.4% with HR2 = 1.05 (it corresponds to 
coronary revascularization, while HR for unstable angina is 1.10). 
The ARE(ε*, ε1) is explored for these parameter values. For all different shapes 
of the time-to-event distributions (9 combinations including increasing, constant and 
decreasing hazard functions) and correlation values ranging from 0.15 to 0.75 (63 
scenarios), it is found that the ARE is always less than 1.1. Following the rule of 
Gómez and Lagakos, the benefits of using the CE, ε*, over the RE, ε1, are marginal 
and probably too small to justify adding ε2. 
The use of ε* would be justified in the case that HR2 ≤ 0.85, for all other 
parameters fixed (i.e., p1 = 8.2%, HR1 = 0.81, p2 = 10.4%) (see Figure 2). However, if 
HR2 ≥ 0.95 not even an expected frequency of 20% for the AE ε2, would justify the 
use of ε*. If HR2=0.9, ε* would only be justified if p2 ≥ 20% and the association 
between ε1 and ε2 is very weak (not shown).  
	
 
 
 
Figure 2: ARE of composite versus relevant endpoint for a range of Spearman correlation coefficients and different values of HR2 
for the parameters of Case Study 1 (p1 = 0.082, HR1 = 0.81, p2 = 0.104) and marginal increasing hazards. 
	
 
 
Spearman 
correlation 
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Thus, under these circumstances, the additional components of coronary 
revascularization or hospitalization for unstable angina on the primary endpoint would 
had only been recommended if the expected beneficial effect of succinobucol on 
these components would have been approximately as strong as the expected effect 
on cardiovascular death, resuscitated cardiac arrest, MI or stroke. Based on these 
findings one should be cautious of adding components to the primary endpoint of 
relatively little importance.  
 
Case Study 2: Treating haemorrhagic complications during primary 
percutaneous coronary intervention (PCI) in acute myocardial infarction  
The Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial 
Infarction (HORIZONS-AMI) study is a prospective, open label, randomized, 
multicenter trial in patients with ST-segment elevation myocardial infarction presented 
within 12 hours after the onset of symptoms7. In this study, 3602 patients were 
assigned to treatment with heparin plus a glycoprotein IB/IIa inhibitor (n = 1802) or the 
alternative treatment of bivalirudin alone (n = 1800). The interest lies on whether 
hemorrhagic complications are reduced, when using bivalirudin alone. Two primary 
30-day endpoints were prespecified: 1) major bleeding, denoted by ε1 and 2) net 
adverse clinical events (NACE), denoted by ε*, a composite of major bleeding and 
major adverse cardiovascular events (MACE). MACE, denoted by ε2, is composed, in 
this trial, of death, reinfarction, target vessel revascularization for ischaemia and 
stroke. In this case, while major bleeding is the relevant event of interest, the 
composite ε* takes into account all other additional adverse clinical events including 
death. According to the results, MACE is almost identical in the two groups (98 vs 99 
events, p = 0.95) while major bleeding is statistically significantly lower in the 
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bivalirudin alone group (89 vs 149 events, p<0.001). The comparison of NACE (166 
vs 218 events, p = 0.005) between treatment groups is found statistically significant, 
and as correctly mentioned by the authors, this is entirely driven by the effect on 
major bleeding. The risk taken by the researchers of combining the endpoint of 
interest with an endpoint on which treatments have no differential effect, is 
demonstrated using this study.  
The probability of observing a major bleeding event, ε1, is p1 = 8.3% with 
hazard ratio HR1 = 0.6, while the probability of observing a MACE event, ε2, is p2 = 
5.5% with HR2 = 1. MACE is occurring with smaller frequency than the RE and in 
addition the treatment does not have an effect on it. Under these parameter values 
the ARE(ε*, ε1) is examined for 21 scenarios corresponding to different shapes of the 
time-to-event distributions (including decreasing, constant and increasing hazards) 
and correlation values ranging from 0.15 to 0.75. In the vast majority of cases the 
ARE between a major bleeding event and a MACE event, is less than 1.1, meaning 
that the use of the CE (NACE) is not recommended.  
Other scenarios were also explored under all above combinations of 
distributional shapes and correlation values. First, for higher values of the probability 
of observing a MACE event, ε2, (5.5% ≤ p2 ≤ 8.0%), a similar pattern emerges, with a 
sparse number of cases (5 of 84 scenarios), with ARE above 1.1, leading to the 
recommendation of NACE, with all cases occurring for correlation of 0.75. Second, 
the ARE(ε*, ε1) was also explored for larger beneficial effects on MACE (0.3 ≤ HR2 ≤ 
0.9) and the ARE value is less than 1.1 except for 11 cases (out of 105). Figure 3 
illustrates the AREs for the values of the parameters of this clinical trial (p1 = 8.3%, 
HR1 = 0.6, p2 = 5.5%) and for marginal increasing hazards. Globally, in 88% of the 
scenarios, the use of ε1 is recommended.  
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Figure 3: ARE of composite versus relevant endpoint for a range of Spearman correlation coefficients and different values of HR2 
for the parameters of Case Study 2 (p1 = 0.083, HR1 = 0.6, p2 = 0.05) and marginal increasing hazards. 
	
	
It is clear that the chosen primary endpoint ε* for the efficacy of bivalirudin 
alone in this study gave “unexpected good” results and that it was a matter of “luck” 
not to have a diluted effect in NACE since the ARE can be as low as 0.2 if the 
beneficial effect on MACE is 0.5, meaning that major bleeding as a primary endpoint 
can be as much as 5 times more efficient than NACE. 	
One could wonder under which circumstances the composite NACE would 
have been a better, more efficient choice, and by running all the ARE computations 
for different values of the frequency of observing an AE, we find that for the composite 
NACE to be justified, both a high frequency of observing MACE events as large as 
70% and a strong association between bleeding and MACE, are needed.  
	
	
	
	
	
	
Spearman 
correlation 
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Results 
The absolute number and frequency of occurrence of each endpoint (CE and 
components of interest), the corresponding hazard ratios (HRs) and p-values 
between groups compared in the trial, were extracted from each publication in Table 
1. The choice between CE and RE in the design of future trials on similar populations 
and questions of interest, can be guided by the estimated ARE based on the 
observed values of endpoint control group frequency and HRs from the reviewed 
trials. Interesting cases of trials leading to a significant result for the CE while 
non-significant for the RE or significant for the RE and non-significant for the CE, are 
described later in this section. 
Reviewed superiority trials leading to non-significant differences both on the 
RE and CE8-11, are not of particular interest, since at the design stage for any future 
superiority trial, the anticipated HRs under investigation will differ from one. 
In addition, trials that led to opposite effects in the RE and AE, will not be 
explored in this context, since in such cases, designing the study based on the CE is 
not useful. An illustration of why such a choice would be problematic is given by a 
study exploring the effect of metopropol succinate in patients undergoing non-cardiac 
surgery with (or at risk of) atherosclerotic disease12. In that trial, the primary CE, ε*, 
(cardiovascular death, non-fatal MI, and non-fatal cardiac arrest) shows a treatment 
benefit (HR*=0.84), driven entirely by the AE (MI), ε2, (p2=5.7%; HR2=0.73), while 
death (ε1) shows a harmful effect (p1=2.3%; HR1=1.33). The interpretation of the 
results and the study conclusion, as would be expected, rather than focusing on the 
CE significant result, is instead dramatically affected by the observed harm on 
survival.  
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In the reviewed studies, specific combinations of the control group frequencies 
for the RE(p1) and AE(p2) with corresponding HR values, emerged. The AREs were 
estimated for these combinations to serve as a guide for the design of future trials.  
Death from Cardiovascular causes or death from any cause was included in 
the composite primary endpoint in 46 trials. When death is the RE, the ARE of a CE 
including any of MI, Stroke or hospitalization as AEs, was explored for different 
shapes of time to event distributions, and a range of correlations between times to ε1 
and ε2.. 
For the majority of trials, the frequency of death was relatively low (median 
4%), with the exception of 3 trials where death was very frequent (above 20%). For 
observed frequencies up to 12%, it is reasonable to attempt to use a CE and 
examples of the trials are discussed next. 
For the relatively low frequency of MI (ε2) (up to 12%) for all HR combinations 
found in the trials, the CE of death and MI is almost always justified based on the ARE 
except for the case where death and MI present with the same frequency and the 
beneficial effect on death is higher than on MI (HR2>HR1).  
For particularly low frequency of stroke, ε2, found in the trials (0.5%), the CE of death 
and stroke is always justified in the cases that the beneficial effect on stroke is higher 
than on death (HR2<HR1). The same is true for the higher frequency of stroke (12%), 
while the CE is also justified when the beneficial effect on stroke is slightly less than 
on death but death presents with lower frequency. 
When examining the CE of death and hospitalization, in the cases that 
hospitalization is occurring with high frequency (18% to 48%), a different pattern 
emerges. The CE is justified in the cases that the HR for death is above 0.8, while for 
hospitalization is below 0.9. Even in the case of HR1=0.70, for very low frequency of 
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death (p1=3%), when the frequency of hospitalization is high (p2=48%), the composite 
is not only justified for HR2=0.70 as would be expected, but also for HR2=0.9. For a 
substantial benefit on death coupled with low frequency (HR1=0.5; p1=6%), when the 
frequency of hospitalization is high (p2=39%) even for a smaller benefit for 
hospitalization (HR2=0.70), the CE is justified, while when the benefit on 
hospitalization becomes even smaller (HR2=0.90), using death as a primary endpoint 
is preferred. The CE is not justified when HR2>HR1 provided that the frequency of 
death is higher (p1=12%). 
 
Discussion of specific trials 
In total, 5 clinical trials used as primary endpoint the CE of death and MI, with 
frequency of the CE ranging from 5% to 18%10-14. The corresponding follow-up period 
for 3 of the trials was 30 days: for patients with ST-segment elevation acute MI 
(STEMI) without reperfusion therapy13, for intermediate to high risk patients with 
coronary artery bypass graft surgery10, and for patients undergoing non-cardiac 
surgery with (or at risk of) atherosclerotic disease12. For stable patients after acute 
phase of MI with late occluded infarction related arteries11 and for hypertensive 
patients14, the follow-up period was 4 and 5.5 years, respectively.  
In the clinical trial testing fondaparinux in STEMI patients13, the RE of death 
and the AE of Myocardial re-infarction at 30 days occurred in 12.5% and 3.7% of 
control patients, respectively. The CE occurred in 15.1% of control patients, indicating 
a weak correlation between RE and AE. The corresponding hazard ratios (HR1=0.83 
and HR2=0.66) were both not significantly different than 1. The increased number of 
events for the CE and the same direction of benefit for both components, led to a 
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statistically significant HR* of 0.80. In this trial, the use of the CE, is clearly indicated 
by the ARE in 100% of the simulations.  
In testing atorvastatin in hypertensive patients14, a statistically significant 
benefit on the CE of fatal coronary heart disease (CHD) and non-fatal MI was found 
(p*=4.8%, HR*=0.64), while a trend was identified in the RE of cardiovascular 
mortality (p1=3.2%, HR1=0.84). Use of the CE would be justified here for the AE of 
non-fatal MI, since the ARE is larger than 1.1 for i) HR2 less than 0.8 and any p2 up to 
0.6, ii) p2 larger than 13% and any HR2 as high as 0.9.  
Three prevention studies assessed the benefit on the risk of cardiovascular 
disease of i) vitamins E & C in men above 50 years old15, ii) intensive glucose control 
in veterans with type 2 diabetes16, and iii) low-dose aspirin in the prevention of 
atherosclerotic events in patients with type 2 diabetes17. Composite primary outcome 
was used in each of these studies, with a major cardiovascular event defined as 
nonfatal MI, nonfatal stroke, death from CV15, or MI, stroke, death from CV, 
congestive heart failure, surgery for vascular disease, inoperable coronary disease, 
and amputation for ischemic gangrene16, while the CE of atherosclerotic events was 
defined as fatal and nonfatal ischemic heart disease, fatal or nonfatal stroke, and 
peripheral arterial disease17. 
The latter trial, could be considered an outlier, due to the combination of a very 
low frequency of fatal CV events (p1=0.008), yet significantly different between 
groups (HR1=0.10, p=0.0037). Under these extreme conditions, the use of the RE 
would have been justified based on the very low HR1, while the use of the CE would 
have been justified based on the very low frequency of events. The ARE points to the 
clear choice of the CE for HR2≤0.2, and the clear choice of the RE for HR2≥0.8, while 
for HR2 values between 0.2 and 0.8, the CE is recommended as HR2 increases for 
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progressively higher values of p2 .The CE occurred in 6.7% of control patients, 
indicating a weak correlation between RE and AE, leading to an HR* of 0.80, but not 
statistically significant. Nevertheless, an assumption of a treatment effect at such an 
extreme would be difficult to justify at the design stage, although it could be taken 
under consideration for the next trial designed on this question.  
Finally, in only 4 trials, death from CV or death from any cause was used as 
the individual primary or co-primary endpoint8,9,18,19. The frequency of cardiovascular 
death or any death in two of the trials9,19 on patients with NYHA class II-IV Chronic 
Heart Failure, or Atrial Fibrillation & NYHA class II or IV heart failure, was 25% and 
29% respectively. In such cases of high death frequency, the use of the CE is justified 
only when the anticipated treatment benefit for the AE is similar or higher than the one 
for survival. Such is the case in the trial exploring the effect of n-3 polyunsaturated 
fatty acids in patients with chronic heart failure19, where the use of the CE of death 
and admission to hospital for CV reasons as co-primary endpoint, would be fully 
supported by the ARE. 
On the contrary, for a particularly low frequency of death (p1<1%) and 
moderate or low magnitude of benefit, as already discussed, the CE is almost always 
justified. Surprisingly, in the Influenza Vaccination study on patients with Confirmed 
Coronary Artery Disease (CAD)18, the primary endpoint used was death from CV, 
although its frequency was <1%. A significant benefit of vaccination was detected on 
the secondary CE of Coronary Ischemic event (MACE and hospitalization for 
myocardial ischemia). Use of this CE would have been recommended at the design 
stage by the calculation of ARE.  
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Recommendations 
We present recommendations for future design choice between CE and RE for 
cardiovascular clinical trials which use CEs as an option for the primary endpoint, 
include death as the RE and add other non fatal endpoints such as MI, stroke, 
hospitalization, etc. We are focusing on the 44 clinical trials out of the 47 in Table 2 
having death as part of the primary CE and observed frequency of death less than 
15%. 
In all cases, computations have been done modeling the marginal laws of the 
times to ε1 and ε2 as Weibull, representing decreasing, constant and increasing 
hazard functions. Previously examined scenarios for this situation (Case 3, Gómez 
and Lagakos), are combined with the parameter combinations encountered in the 
current report to provide recommendations for the cardiovascular area trials. 
Gómez and Lagakos reproduced several frequency situations by taking 
probabilities p1 and p2 equal to 0.05, 0.15, 0.30 and 0.50. The relative treatment effect 
on the RE was set to HR1=0.5 or 0.7, and it was combined with six different values for 
HR2  reproducing situations where the beneficial effect on the AE was larger, the 
same or smaller. These parameter values were combined with different degrees of 
dependence between times to ε1 and to ε2. Based on all these combinations, it is 
observed that the ARE decreases when the correlation between the two endpoints 
increases and when the relative effect of treatment on the AE is smaller. The 
observed relative frequencies of death among the 44 studied clinical trials were 
between 0.002 and 0.15. The observed relative frequencies of the AEs (MI, Stroke, 
Hospitalization and TVR) were between 0.002 and 0.48. Concerning the relative 
treatment effects it was found that some of the RCTs had an observed HR larger than 
1 (19 out of 44). At the design stage of a clinical trial an anticipated value of HR>1 will 
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not be a value of interest neither for death nor for the AEs. For computations we are 
using 0.99 to represent negligible relative treatment effects. Among the clinical trials 
with HR<1, we have found relative treatment effects for death as small as 0.1 and as 
large as 0.98 and between 0.35 and 0.94 for the AEs. 
Since not all the combinations of frequencies and relative treatment effects 
(p1,HR1) or (p2,HR2) were found in the studied RCTs, we did restrict our computations 
to published pairs of values (p, HR). Figures 4 and 5 reproduce the possible pairs (p, 
HR) for death and for Stroke, MI, Hospitalizations and TVR, extracted from the 44 
clinical trials, after excluding pairs with HR>1. They represent the range of 
combinations which have been used to compute the ARE.  
 
 
 
Figure 4: Plot for the probability of occurrence of Death in the control group versus the corresponding hazard ratio. Clinical trials 
with HR >1 are excluded. Chosen pairs of values for the computations are: (p1,HR1) = (0.005,0.4), (0.05,0.99), (0.03,0.7), 
(0.03,0.8), (0.03,0.99), (0.06.0.5), (0.06,0.7), (0.06,0.8), (0.06,0.9), (0.06,0.99), (0.09,0.7), (0.09,0.9), (0.12,0.8), (0.12,0.9), 
(0.12,0.99), (0.15,0.8).   
21 
 
 
 
Figure 5: Plot for the probability of occurrence of Stroke, MI, Hospitalizations and TVR in the control group versus the 
corresponding hazard ratio. Clinical trials with HR >1 are excluded. Chosen pairs of values for the computations are: (p2,HR2) = 
(0.005,0.3), (0.005,0.5), (0.005,0.6), (0.005,0.8), (0.005,0.99), (0.03,0.6), (0.03,0.8), (0.03,0.9), (0.03,0.99), (0.06,0.7), 
(0.06,0.8), (0.06,0.9), (0.06,0.99), (0.12,0.8), (0.12,0.9), (0.12,0.99), (0.18,0.9), (0.27,0.9), (0.39,0.7), (0.48,0.9). The three last 
pairs not shown in the figure. 
 
Recommendations for cardiovascular clinical trials 
Aiming to provide a useful guide to help the investigator in the planning of a clinical 
trial, we discuss the recommendations in terms of the values of the anticipated hazard 
ratios HR1 and HR2, and, when needed, in terms of the anticipated probabilities of 
occurrence p1 and p2.  
It would never be recommended to use a CE by adding an AE with anticipated 
frequency value as small as 0.005 and/or an HR close to 1. One has also to keep in 
mind that the association between time to ε1 and time to ε2 could play an important 
role and that decisions based on hazard plots as the ones in Figures 2 and 3 are 
recommended. Furthermore, the recommendations are to be taken cautiously since 
very infrequent events (p in the order of 0.005), frequencies of death with order of 
magnitude larger than the frequency of AE (p1/p2>12) and/or unlikely very frequent 
endpoints (p larger than 0.35) could reverse the direction of the recommendation. 
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Keeping in mind that the specific decision for a given trial has to be based on a 
thorough study as has been shown in the case studies and the results section, a set 
of recommendations on whether to use the RE or the CE is outlined below (see figure 
6): 
 HR2<HR1: the relative treatment effect is greater on the AE than on the RE  CE 
should always be used.  
 HR2=HR1: RE and AE have approximately the same relative treatment effect  CE 
should almost always be used. Only in those cases where the anticipated probability 
for AE has a low frequency (p2≤0.06) and the frequency for RE is between 2 and 5 
times the frequency of the other endpoints (2<p1/p2<5), RE could be a better choice. 
 HR2=HR1+0.1: AE has a slightly smaller effect on treatment than RE RE should 
always be used if p1/p2>=3 and CE should always be used if p1/p2≤0.25. Whenever 
0.25<p1/p2<3 the decision will depend on the anticipated values of the relative 
treatment effect, the frequency of observation of either endpoint along with its 
correlation and to a lesser extent on the shape of the marginal density.  
 HR2=HR1+0.2: AE has a smaller effect on treatment than RE RE should almost 
always be used except when the relative frequency of the AE is extremely higher than 
that of the RE (p1/p2 ≤ 0.06). 
 HR2≥HR1+0.3: AE has a much smaller effect on treatment than RE  RE should 
always be used. 
 
 
 
Figure 6: The horizontal axis represents the values of the HR2 of AE as a function of the HR1 of RE. Each tick summarizes 
several scenarios corresponding to different shapes of the marginal hazards and different degree dependences between RE and 
AE. For each tick we indicate whether it is advisable to adopt CE in preference to RE. * See explanation on text. 
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Discussion 
This study, focused in the cardiovascular research area, explores under which 
circumstances adding other endpoints to a primary endpoint of death would result in a 
more efficient choice. It is clear from our results that, contrary to a common belief, 
adding a frequent event to a primary endpoint of death does not always help and, 
indeed, may even prove harmful. The fact that the CE increases the number of 
events, does not mean, even in the case of a common event rate and similar 
magnitude of the treatment effects, that the required sample size of a trial is reduced 
since, depending on the strength of the association between RE and AE, the ARE is 
not necessarily greater than 1.  
Our methodology implicitly assumes the ARE as the reciprocal ratio of the 
sample sizes needed to attain the same power for a given significance level 20. 
Furthermore, the computation of the sample size is often based on the proportionality 
of the hazards across the two treatment groups based on the primary endpoint. It is 
important to emphasize that this assumption for both the RE and the AE does not 
imply the proportionality on the CE, hence alternative formulas for the computation of 
the sample size if the CE is chosen are needed.  
We also assume that the dependence between the RE and the AE is specified 
by means of a Frank’s Archimedean copula, but also other copulas could be taken 
into consideration21. Of note, at the analysis stage, the presence of competing risks, 
the homogeneity and the strength of association among the components of the CE is 
encouraged .  
We have designed a platform called CompARE to calculate ARE values based 
on the information of the different relevant endpoints together with the anticipated 
values of p1, p2, HR1, HR2 and ρ. The design of CompARE is flexible enough allowing 
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different scenarios to be shown in plots by combining different range of values for the 
parameters. This is a free tool to be used to learn which is the most efficient primary 
endpoint among a set of given ones in an intuitive way. CompARE, written under the 
GNU/LGPL license, allows the user, through HTML forms from the web-based 
application, to introduce the parameter values. Such an interactive web site, still in a 
beta version and available from the second author under request, would allow users 
to enter their own values when designing a clinical trial.  
Finally, it is important to point out that our methodology is only intended for the 
planning phase of the RCT.  
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